
Brian C. DeFelice
Scientist I, Metabolomics – Mass Spectrometry Platform
Brian DeFelice is interested in better understanding the role lipids and metabolites play in human health. At CZ Biohub he is collaborating with investigators from Biohub’s Microbiome Initiative to expand metabolomics capabilities at the hub. To this end, Brian has developed and implemented LC-MS/MS methods used for quantifying metabolites relevant to host-microbe interactions. A key concern of his is the de-orphaning of previously unidentified metabolites. Brian received his Ph.D. in Pharmacology and Toxicology with Oliver Fiehn at UC Davis. He has been studying and practicing mass spectrometry-based metabolomics and lipidomics since 2011.

Juan Moises Sanchez
Senior Research Associate, Metabolomics – Mass Spectrometry Platform
Juan holds a Bachelor’s degree in Chemistry and a Master’s degree in Biomedical Engineering, both from the University of Texas at El Paso. He began his career working as a Project Manager for two environmental engineering firms. As a Project Manager he provided consulting services to both industry and governmental agencies. In 2017, Juan joined Intrexon corporation and transitioned over to Synthetic Biology, with a focus on Stable Isotope Labeling (SIL) enabled metabolomics. Juan left Intrexon in 2020 to join the Chan Zuckerberg Biohub at Stanford University and evolve his passion for metabolomics to the next level.

Frank Rory Kevin McCarthy
Senior Research Associate, Mass Spectrometry Platform
Frank graduated in 2007 with a Bachelor of Science (Honors) degree at the University of New South Wales (UNSW) in Sydney, Australia. He then joined The Institute of Cancer Research (ICR) in London, UK as a Scientific Officer in the Molecular Carcinogenesis Team spending six years working on translational research projects investigating biomarkers in prostate cancer. With a brief hiatus travelling, he then returned to ICR in 2015 in the Protein Networks team as a Higher Scientific Officer where he spent just over two years investigating the mechanisms of drug resistance to different receptor tyrosine kinase inhibitors and was introduced to the world of mass spectrometry. This passion for proteomics-based mass spectrometry was recognizable and he joined The Chan Zuckerberg Biohub at Stanford University in 2019 as a Senior Research Associate working on protein subcellular localization, translocation, and proteomic mapping as part of The Cell Atlas Initiative.